NASDAQ:MGTA Magenta Therapeutics (MGTA) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free MGTA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.68▼$0.7650-Day Range$0.36▼$0.7652-Week Range$0.32▼$2.07Volume376,000 shsAverage Volume848,835 shsMarket Capitalization$42.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Magenta Therapeutics alerts: Email Address Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About Magenta Therapeutics Stock (NASDAQ:MGTA)Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Read More Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. MGTA Stock News HeadlinesApril 22, 2024 | msn.comWhen Red-Hot Isn't Enough: New Government Heat Risk Tool Sets Magenta as Most Dangerous LevelApril 13, 2024 | msn.comWhat's Included In T-Mobile's Magenta Max 55+ Plan (And How It Compares To Others)April 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 2, 2024 | msn.comMagenta the horse rescued from Fenland river by fire crews after becoming spookedMarch 26, 2024 | seekingalpha.comPSTX Poseida Therapeutics, Inc.March 20, 2024 | seekingalpha.comDNTH Dianthus Therapeutics, Inc.February 23, 2024 | finanznachrichten.deTEOCO's new framework drives Zero Touch Operational Automation at Magenta TelekomFebruary 22, 2024 | finance.yahoo.comTEOCO's New Framework drives Zero Touch Operational Automation at Magenta TelecomApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."February 16, 2024 | msn.comGerman streamer Joyn lands on Magenta TVFebruary 7, 2024 | macrumors.comT-Mobile Debuts 'Magenta Status' Rewards for SubscribersFebruary 7, 2024 | 9to5mac.comT-Mobile ramps up loyalty rewards with ‘Magenta Status’, here’s what’s includedFebruary 7, 2024 | stockhouse.comT-Mobile Customers Now Have "Magenta Status" - VIP Vibes with One-of-a-Kind Benefits Across Premium Brands and ServicesFebruary 3, 2024 | investing.comViking Therapeutics Inc (VKTX)January 31, 2024 | msn.comT-Mobile's Magenta Max Plan: Is It Really Worth Upgrading?November 29, 2023 | msn.comOperation Magenta: Kent Police issue update following Gosport Memorial Hospital investigationNovember 27, 2023 | msn.comMagenta’s Ellesmere Port extra care scheme celebrates sixth birthdayNovember 21, 2023 | health.usnews.comMagenta HallNovember 21, 2023 | msn.comMagenta Living collaborates with Welsh housing associationNovember 20, 2023 | msn.comMovie Review - Magenta Coal: Promising Series Crashlands At Tail EndNovember 16, 2023 | msn.com£3.6m invested into making Magenta Living houses energy efficientNovember 14, 2023 | msn.comEstate of Stan VanDerBeek, Experimental Filmmaker and ‘Agitator,' Joins Magenta PlainsNovember 14, 2023 | finance.yahoo.comFMR LLC Acquires New Stake in Magenta Therapeutics IncNovember 14, 2023 | msn.comMagenta Living customers complete new life skills programmeNovember 8, 2023 | msn.comMagenta Living launch new digital system to deal with damp and mouldOctober 30, 2023 | msn.com‘Magenta Coal’ lights up Netflix, soars to No. 1 in 24 hoursOctober 25, 2023 | msn.com'Magenta Coal's' unveiled cast: Late Busi Lurayi returns to Netflix dramaSee More Headlines Receive MGTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Magenta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:MGTA CUSIPN/A CIK1690585 Webwww.magentatx.com Phone(857) 201-2700FaxN/AEmployees67Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,460,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-70.88% Return on Assets-57.27% Debt Debt-to-Equity RatioN/A Current Ratio19.49 Quick Ratio19.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.57Miscellaneous Outstanding Shares60,665,000Free Float51,456,000Market Cap$42.44 million OptionableNot Optionable Beta2.12 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Stephen F. Mahoney J.D. (Age 51)MBA, Pres, Chief Financial & Operating Officer and Treasurer Comp: $637.21kShan WuHead of Investor RelationsMr. Thomas W. Beetham J.D. (Age 53)MBA, Chief Legal Officer & Sec. Ms. Catherine MonaghanHead of Clinical Devel. OperationsMr. Jim HaneySr. Director of Investor RelationsKey CompetitorsLianBioNASDAQ:LIANBioLineRxNASDAQ:BLRXTevogen BioNASDAQ:TVGNKinnate BiopharmaNASDAQ:KNTENGM BiopharmaceuticalsNASDAQ:NGMView All Competitors MGTA Stock Analysis - Frequently Asked Questions How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics, Inc. (NASDAQ:MGTA) posted its earnings results on Thursday, November, 4th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.02. When did Magenta Therapeutics' stock split? Magenta Therapeutics shares split on Thursday, September 7th 2023. The 2-1 split was announced on Thursday, September 7th 2023. The newly issued shares were issued to shareholders after the market closes on Thursday, September 7th 2023. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What is Jason Gardner's approval rating as Magenta Therapeutics' CEO? 3 employees have rated Magenta Therapeutics Chief Executive Officer Jason Gardner on Glassdoor.com. Jason Gardner has an approval rating of 60% among the company's employees. This puts Jason Gardner in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), ADMA Biologics (ADMA), NVIDIA (NVDA), Pfizer (PFE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN) and CRISPR Therapeutics (CRSP). When did Magenta Therapeutics IPO? Magenta Therapeutics (MGTA) raised $100 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:MGTA) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Magenta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
